Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers - Inria - Institut national de recherche en sciences et technologies du numérique
Journal Articles European Journal of Cancer Year : 2023

Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers

Edith Borcoman
  • Function : Author
Institut Curie [Paris]
Ana Lalanne
  • Function : Author
Institut Curie [Paris]
CIC1428 IGR-CURIE
Jean-Pierre Delord
  • Function : Author
Institut Universitaire du Cancer de Toulouse - Oncopole
Institut Claudius Regaud
Philippe Cassier
Centre de Recherche en Cancérologie de Lyon
Centre Léon Bérard [Lyon]
Frédéric Rolland
CRLCC René Gauducheau
Sébastien Salas
  • Function : Author
Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique
Jean-Marc Limacher
Hôpital pasteur [Colmar]
Olivier Capitain
  • Function : Author
Institut de Cancérologie de l'Ouest [Angers/Nantes]
Olivier Lantz
Institut Curie [Paris]
Christina Ekwegbara
  • Function : Author
Emmanuelle Jeannot
Immunité et cancer
Joanna Cyrta
Institut Curie [Paris]
Carine Tran-Perennou
  • Function : Author
Institut Curie [Paris]
Zahra Castel-Ajgal
  • Function : Author
Grégoire Marret
Université Paris Descartes - Faculté de Médecine
Eliane Piaggio
  • Function : Author
Immunité et cancer
Maud Brandely
  • Function : Author
Transgene SA [Illkirch]
Annette Tavernaro
  • Function : Author
Hakim Makhloufi
  • Function : Author
Kaidre Bendjama
Transgene SA [Illkirch]
Christophe Le Tourneau

Domains

Cancer

Linh Nguyen Phuong  : Connect in order to contact the contributor

https://hal.science/hal-04382182

Submitted on : Tuesday, January 9, 2024-12:11:14 PM

Last modification on : Thursday, September 12, 2024-3:19:24 PM

No file

Dates and versions

hal-04382182 , version 1 (09-01-2024)

Identifiers

Cite

Edith Borcoman, Ana Lalanne, Jean-Pierre Delord, Philippe Cassier, Frédéric Rolland, et al.. Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers. European Journal of Cancer, 2023, 191, pp.112981. ⟨10.1016/j.ejca.2023.112981⟩. ⟨hal-04382182⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

CNRS INRIA UNIV-AMU UNIV-LYON1 ICR FNCLCC CURIE PAOLI_CALMETTES ICO GAUDUCHEAU INRIA2 PSL CRCL CRCM UDL CRCL-EQUIPE-Y-GRINBERG UNIV-UT3 UT3-TOULOUSEINP
54 View
0 Download

Altmetric

Share

More